Marketing and distribution would not be a big issue as there is only a small addressable population and really not many if any competing products. If we can duplicate the same result from the previous trial and approve for sale I think we will have patients lining up for ANP drug.
If a small Aussie biotech can develop and commercialized drug that outperform drugs from multi billion US pharma which we will, marketing and distribution to 10K-15K patients should be a breeze and least of our worry.
I am dreaming here but can ANP be the next CSL, Cochlear or Promedicus? Only time will tell.
Chart, page-4264
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 8.0¢ | 7.7¢ | $134.7K | 1.732M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99278 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 122500 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 8.0¢ | 7.7¢ | 70281 | ||
| Last updated 15.51pm 07/05/2024 ? | |||||
| PER (ASX) Chart |